Navio MD review

Navio does the thing this site keeps asking for: it tells you which pharmacy dispenses your prescription, by name, before you buy. That single disclosure is worth more than most of the trust signals providers advertise, because it is checkable. It also puts a compounded plan beside brand Ozempic, Zepbound and Mounjaro on one screen, so the gap between compounded and brand is visible rather than something you assemble yourself. Where it falls short is the shape of the price. Everything is an "as low as", which means a patient starting at a low dose is quoted honestly and a patient contemplating a higher one is quoted nothing at all — the rungs above the floor are published nowhere. Check state availability early, too: this is not a fifty-state operation, though it is refreshingly direct about that, and says you will not be charged if you are outside its footprint.

Vs median

$14/mo above the $175 median across the 299 of 548 programs here that publish a plain monthly rate

Market

$59–$1,300/mo is the full published spread on this site

Structure

Quotes off the lowest dose

Consult

Included in the price

Dietitian

Not confirmed

Labs

Not required

Pricing

Check plan terms

Navio MD names its pharmacy: The Pharmacy Hub. No bloodwork is required before you start. A clinician review is included in the price.

Navio MD runs a virtual clinic covering both compounded and brand-name GLP-1s, putting a compounded tirzepatide plan beside brand Ozempic, Zepbound and Mounjaro so the cash difference between compounded and brand is visible on one screen. Patients meet a licensed provider, and comfort medications are folded into the starting-dose plans. Its most useful disclosure is one most competitors avoid: it names the pharmacy that dispenses every prescription. Its least useful is the pricing form — each product is advertised at an "as low as" rate, which is the floor of a ladder whose higher rungs are not published, so a patient cannot see what a dose increase does to the bill.

EVERY PRICE IS A FLOOR. All four products are advertised "as low as", and no higher-dose rung is published at any figure, so someone holding at a low dose cannot tell whether staying low saves anything

• Not available in all 50 states — the site says it is "actively working to expand", which means coverage today is narrower than a national telehealth brand implies
• The brand Mounjaro rate is an order of magnitude above the compounded tirzepatide rate, and the page does not explain what accounts for the gap
• No LegitScript seal is displayed
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

Navio MD is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• What microdosing GLP-1 costs
• The true annual cost of a plan